H
Henry Punzi
Researcher at University of Texas Southwestern Medical Center
Publications - 38
Citations - 504
Henry Punzi is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Blood pressure & Albuminuria. The author has an hindex of 11, co-authored 34 publications receiving 346 citations.
Papers
More filters
Journal ArticleDOI
Urine Markers of Kidney Tubule Cell Injury and Kidney Function Decline in SPRINT Trial Participants with CKD.
Rakesh Malhotra,Ronit Katz,Vasantha Jotwani,Walter T. Ambrosius,Kalani L. Raphael,William E. Haley,Anjay Rastogi,Alfred K. Cheung,Barry I. Freedman,Henry Punzi,Michael V. Rocco,Joachim H. Ix,Joachim H. Ix,Michael G. Shlipak +13 more
TL;DR: Urine markers of tubule cell injury provide information about risk of subsequent loss of kidney function, beyond the eGFR and urine albumin, in persons with nondiabetic CKD who participated in the Systolic Blood Pressure Intervention Trial (SPRINT).
Journal ArticleDOI
Markers of kidney tubule function and risk of cardiovascular disease events and mortality in the SPRINT trial
Pranav S. Garimella,Alexandra K. Lee,Walter T. Ambrosius,Udayan Bhatt,Alfred K. Cheung,Michel Chonchol,Timothy E. Craven,Amret T. Hawfield,Vasantha Jotwani,Anthony A. Killeen,Henry Punzi,Mark J. Sarnak,Barry M. Wall,Joachim H. Ix,Joachim H. Ix,Michael G. Shlipak,Michael G. Shlipak +16 more
TL;DR: Among non-diabetic persons with CKD, biomarkers of tubular function are associated with CVD events and mortality independent of glomerular function and albuminuria.
Journal ArticleDOI
Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study:
Henry Punzi,Joel M. Neutel,Dean J. Kereiakes,Ali Shojaee,William F. Waverczak,Robert Dubiel,Jen-Fue Maa +6 more
TL;DR: The study drug was well tolerated with few adverse events, and an AML/OM-based titration regimen effectively reduces BP in patients with hypertension.
Journal ArticleDOI
Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension.
TL;DR: Using a higher dose of a thiazide diuretic with a long‐acting angiotensin receptor blocker as a useful strategy for improving hypertension control is supported.
Journal ArticleDOI
Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension
TL;DR: Eprosartan 600 mg once daily was both well tolerated and effective, providing significant blood pressure reduction 24 hours after dosing in patients with mild-to-moderate systemic hypertension, regardless of age.